Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Go back to Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.44 +0.03 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.41 | 52 Week High | $0.04 | |||
| Open | $4.39 | 52 Week Low | $0.00 | |||
| Day High | $4.69 | P/E | N/A | |||
| Day Low | $4.37 | EPS | $-0.09 | |||
| Volume | 1,070,561 | |||||
